JP7796636B2 - ヒトトランスフェリンレセプター結合ペプチド - Google Patents

ヒトトランスフェリンレセプター結合ペプチド

Info

Publication number
JP7796636B2
JP7796636B2 JP2022501104A JP2022501104A JP7796636B2 JP 7796636 B2 JP7796636 B2 JP 7796636B2 JP 2022501104 A JP2022501104 A JP 2022501104A JP 2022501104 A JP2022501104 A JP 2022501104A JP 7796636 B2 JP7796636 B2 JP 7796636B2
Authority
JP
Japan
Prior art keywords
peptide
minutes
amino acid
solid
over
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022501104A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2021167107A1 (https=
Inventor
健一 高橋
英士 余田
秀彦 橋本
紗希 藤山
政輝 大内
菜穂子 中村
ナセル 加藤 バシルディン
直己 澤井
武 江原
正訓 多久和
圭一 舛屋
慎之介 稲葉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
JCR Pharmaceuticals Co Ltd
Peptidream Inc
Original Assignee
JCR Pharmaceuticals Co Ltd
Peptidream Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by JCR Pharmaceuticals Co Ltd, Peptidream Inc filed Critical JCR Pharmaceuticals Co Ltd
Publication of JPWO2021167107A1 publication Critical patent/JPWO2021167107A1/ja
Priority to JP2025197068A priority Critical patent/JP2026032056A/ja
Application granted granted Critical
Publication of JP7796636B2 publication Critical patent/JP7796636B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A61K49/0043—Fluorescein, used in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022501104A 2020-02-22 2021-02-22 ヒトトランスフェリンレセプター結合ペプチド Active JP7796636B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025197068A JP2026032056A (ja) 2020-02-22 2025-11-17 ヒトトランスフェリンレセプター結合ペプチド

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020028879 2020-02-22
JP2020028879 2020-02-22
PCT/JP2021/006709 WO2021167107A1 (ja) 2020-02-22 2021-02-22 ヒトトランスフェリンレセプター結合ペプチド

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025197068A Division JP2026032056A (ja) 2020-02-22 2025-11-17 ヒトトランスフェリンレセプター結合ペプチド

Publications (2)

Publication Number Publication Date
JPWO2021167107A1 JPWO2021167107A1 (https=) 2021-08-26
JP7796636B2 true JP7796636B2 (ja) 2026-01-09

Family

ID=77390874

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022501104A Active JP7796636B2 (ja) 2020-02-22 2021-02-22 ヒトトランスフェリンレセプター結合ペプチド
JP2025197068A Pending JP2026032056A (ja) 2020-02-22 2025-11-17 ヒトトランスフェリンレセプター結合ペプチド

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025197068A Pending JP2026032056A (ja) 2020-02-22 2025-11-17 ヒトトランスフェリンレセプター結合ペプチド

Country Status (9)

Country Link
US (1) US20230203098A1 (https=)
EP (1) EP4108676A4 (https=)
JP (2) JP7796636B2 (https=)
CN (1) CN115151556A (https=)
AU (1) AU2021224412A1 (https=)
CA (1) CA3171988A1 (https=)
IL (1) IL295797A (https=)
TW (1) TW202140513A (https=)
WO (1) WO2021167107A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2023022234A1 (https=) * 2021-08-19 2023-02-23
US20240390508A1 (en) * 2021-08-21 2024-11-28 Takeda Pharmaceutical Company Limited Human transferrin receptor binding peptide-drug conjugate
US20240366775A1 (en) 2021-08-24 2024-11-07 Peptidream Inc. Human transferrin receptor binding antibody-peptide conjugate
EP4230638A1 (en) * 2022-02-16 2023-08-23 Lipotrue, S.L. Peptides and compositions for use in cosmetics
WO2024043341A1 (ja) 2022-08-26 2024-02-29 ペプチドリーム株式会社 シクロアルキン誘導体
EP4626906A1 (en) * 2022-11-29 2025-10-08 Vacino Biotech Co., Ltd. Transporter peptides and application thereof
TW202434613A (zh) * 2023-02-17 2024-09-01 日商肽夢想股份有限公司 人類運鐵蛋白受體結合肽
CN120826410A (zh) * 2023-03-17 2025-10-21 富士胶片株式会社 环肽或其盐及它们的利用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012105595A1 (ja) 2011-02-02 2012-08-09 公益財団法人微生物化学研究会 血液脳関門を透過する薬物輸送体、ペプチド及びその用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60147718A (ja) 1984-01-12 1985-08-03 Seikosha Co Ltd 太陽電池付きカラ−表示素子
US5525491A (en) 1991-02-27 1996-06-11 Creative Biomolecules, Inc. Serine-rich peptide linkers
AU656230B2 (en) * 1991-10-11 1995-01-27 F. Hoffmann-La Roche Ag Cyclic vasoactive peptides
JPH06228199A (ja) 1992-11-27 1994-08-16 Takeda Chem Ind Ltd 血液脳関門通過可能なペプチド結合体
US20090087878A9 (en) * 1999-05-06 2009-04-02 La Rosa Thomas J Nucleic acid molecules associated with plants
BR0116024A (pt) 2000-12-07 2005-12-13 Lilly Co Eli Proteìna de fusão heteróloga e uso da mesma
US8188260B2 (en) 2005-12-06 2012-05-29 The University Of Tokyo Versatile acylation catalytic RNAs and uses thereof
BRPI1014253A2 (pt) * 2009-07-02 2016-04-12 Merz Pharma Gmbh & Co Kgaa polinucleotídeo codificado um polipeptídeo de neurotoxina, vetor, célula hospedeira, anticorpo, uso de um polinucleotídeo, método para a fabricação de um polipeptídeo de neurotoxina e método para a fabricação de um medicamento
JP5818237B2 (ja) 2010-09-09 2015-11-18 国立大学法人 東京大学 Ｎ−メチルアミノ酸およびその他の特殊アミノ酸を含む特殊ペプチド化合物ライブラリーの翻訳構築と活性種探索法
WO2012150960A1 (en) 2011-05-05 2012-11-08 Avi Biopharma, Inc. Peptide oligonucleotide conjugates
WO2013141965A1 (en) * 2012-03-21 2013-09-26 Baxter International Inc. Tfpi inhibitors and methods of use
RU2711552C2 (ru) 2012-08-29 2020-01-17 Ф. Хоффманн-Ля Рош Аг Шаттл для гематоэнцефалического барьера
EP2952582A4 (en) 2013-01-30 2016-11-16 Peptidream Inc FLEXIBLE DISPLAY METHOD
CN103254280A (zh) * 2013-03-07 2013-08-21 广州暨南大学医药生物技术研究开发中心 具有肿瘤细胞靶向结合能力的短肽及其应用
TWI769982B (zh) 2015-06-24 2022-07-11 日商Ｊｃｒ製藥股份有限公司 通過血腦障壁之抗人類運鐵蛋白受體抗體
AU2017385274B2 (en) * 2016-12-26 2024-02-22 Jcr Pharmaceuticals Co., Ltd. Fusion protein including BDNF
AU2019215782A1 (en) 2018-02-05 2020-07-16 Jcr Pharmaceuticals Co., Ltd. Method for delivering drug to muscle

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012105595A1 (ja) 2011-02-02 2012-08-09 公益財団法人微生物化学研究会 血液脳関門を透過する薬物輸送体、ペプチド及びその用途

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ZHANG, Y., et al.，Dual-modified liposome codelivery of doxorubicin and vincristine improve targeting and therapeutic efficacy of glioma，Drug Delivery，2017年，Vol. 24，pp. 1045-1055

Also Published As

Publication number Publication date
US20230203098A1 (en) 2023-06-29
JP2026032056A (ja) 2026-02-25
JPWO2021167107A1 (https=) 2021-08-26
EP4108676A4 (en) 2024-06-05
IL295797A (en) 2022-10-01
EP4108676A1 (en) 2022-12-28
AU2021224412A1 (en) 2022-09-15
CA3171988A1 (en) 2021-08-26
WO2021167107A1 (ja) 2021-08-26
TW202140513A (zh) 2021-11-01
CN115151556A (zh) 2022-10-04

Similar Documents

Publication Publication Date Title
JP7796636B2 (ja) ヒトトランスフェリンレセプター結合ペプチド
US20240366775A1 (en) Human transferrin receptor binding antibody-peptide conjugate
JP2025102922A (ja) 新規ｌｒｐ１結合ペプチド
WO2025116046A1 (ja) ペプチド及び当該ペプチドを含むコンジュゲート
EP4389758A1 (en) Human transferrin receptor?binding peptide
EP3433259B1 (en) Conjugates of tacrolimus, their compositions, and their uses
HK40083520A (en) Human transferrin receptor binding peptide
US12415834B2 (en) GhR-binding peptide and composition comprising same
EP4667483A1 (en) Human transferrin receptor-binding peptide
US20260116920A1 (en) Human transferrin receptor binding peptide
HK40105891A (zh) 人转铁蛋白受体结合抗体-肽缀合物
HK40105341A (zh) 人转铁蛋白受体结合肽

Legal Events

Date Code Title Description
AA64 Notification of invalidation of claim of internal priority (with term)

Free format text: JAPANESE INTERMEDIATE CODE: A241764

Effective date: 20221012

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221018

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240131

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250128

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250326

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250523

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250902

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251117

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251202

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251203

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251209

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251223

R150 Certificate of patent or registration of utility model

Ref document number: 7796636

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150